AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 291: R1644-R1650, 2006. First published July 6, 2006; doi:10.1152/ajpregu.00511.2005
0363-6119/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/R1644    most recent
00511.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimayuga, P. C.
Right arrow Articles by Chyu, K.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimayuga, P. C.
Right arrow Articles by Chyu, K.-Y.

INFLAMMATION AND CYTOKINES

Changes in immune responses to oxidized LDL epitopes during aging in hypercholesterolemic apoE(–/–) mice

Paul C. Dimayuga,* Xiaoning Zhao, Juliana Yano, and Kuang-Yuh Chyu*

Atherosclerosis Research Center, Division of Cardiology, Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California

Submitted 12 July 2005 ; accepted in final form 2 July 2006


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Atherosclerosis is a disease associated with aging and is subject to modulation by both the innate and adaptive immune system. The time course of age-dependent changes in immune regulation in the context of atherosclerosis has not been characterized. This study aims to describe alteration of the immune responses to oxidized LDL (oxLDL) during aging that is associated with changes in plaque size and phenotype in apoE(–/–) mice. Mice fed a Western diet were euthanized at 15–17, 36, or >52 wk of age. The descending aortas were stained for assessment of extent of atherosclerosis. Plaque lipid, macrophage, and collagen content were evaluated in aortic sinus lesions. The adaptive immune response to oxLDL was assessed using anti-malondialdehyde-oxidized LDL (MDA-LDL) and copper-oxidized LDL (Cu-oxLDL) IgG, and the innate immune response was assessed using anti-Cu-oxLDL and phosphorylcholine (PC) IgM. Aging was associated with a significant increase in plaque area and collagen content and a decrease in plaque macrophage and lipid content. MDA-LDL IgG significantly increased at 36 wk but was reduced in mice >52 wk. Cu-oxLDL IgG increased with age and IgG-apoB immune complexes were increased in the >52 wk group. Cu-oxLDL and PC IgM significantly increased with age. The expression of splenic cytokines such as IFN-{gamma}, IL-4, and IL-10 increased with age. Our study shows a generalized increase in innate immune responses associated with progression of atherosclerosis and a less inflammatory and less lipid-containing plaque phenotype during aging. The adaptive immune response appeared to be less generalized, with a specific reduction in MDA-LDL IgG.

antibodies; atherosclerosis; oxidized low-density lipoprotein

ATHEROSCLEROSIS IS A DISEASE associated with aging and is modulated by the immune system. Autoantibodies to oxidized LDL (oxLDL) exist in animal models and humans. Experimental immunization using various LDL-related immunogens modulates the progression of the atherosclerotic disease, which points to a protective role for the antibody response to oxLDL elicited by immunization (1, 13, 23, 41). This response has predominantly been viewed as an adaptive response consisting of IgG isotypes. An autoantibody of the IgM class against oxLDL produced by a cell line cloned from apoE(–/–) mice has been identified and is identical to the T15 antibody, which recognizes phosphorylcholine (PC).(31) This indicates that molecular mimicry of oxLDL epitopes occurs naturally and is therefore part of innate immunity, because autoantibodies to PC are known to develop spontaneously (31, 32). Thus those findings also implicate the innate immune system in the development of atherosclerosis.

Although aging-related alteration in immune function has been studied in infectious disease and cancer, the temporal trend of this aging-related change in immune response has not been well characterized in the context of the interaction between aging and immune responses in atherosclerosis. In this study, we have described the progression of the atherosclerotic disease in apoE(–/–) mice with aging that is associated with altered immune responses to oxLDL. Our results showed shifts in immune responses concomitant with changes in the systemic and local indexes of atherosclerotic plaque development with age. The changes occurred in both cellular and antibody-mediated immune responses, with changes in specific antibody titers associated with various indexes of atherosclerosis.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Male apoE(–/–) mice on the C57BL/6 background were purchased (Jackson Laboratory, Bar Harbor, ME) at 6 wk of age and fed a Western-type diet (0.15% cholesterol, 21% fat) throughout the study period. Three groups of apoE(–/–) mice were included in this study: 15- to 17-, 36-, and >52-wk-old mice. All materials were obtained from animals in protocols approved by the Institutional Animal Care and Use Committee. Mice were housed in a pathogen-free environment with sentinel mice periodically checked for infections. Blood was collected before euthanasia. The limited amount of serum available from each mouse prevented the performance of all assays on each sample. The aorta was collected for en face preparation, and the spleen was frozen in liquid nitrogen. The bases of hearts were embedded in OCT, and sections of the aortic sinus were collected.

En face examination of aorta. Aortas were cleaned of connective tissue, cut longitudinally, and stained for lipids. Digital images of the stained aortas were captured, and percent stain area was measured using computer-assisted analysis (Optimas).

Aortic sinus plaque staining. Serial 6-µm-thick frozen sections were collected from the appearance of at least two aortic valves to the disappearance of the aortic valve leaflets. Typically, three consecutive sections were collected on one slide, and a total of 25–30 slides was collected from one mouse. Every fifth slide was grouped for staining. For monocyte/macrophage staining, sections were fixed in ice-cold acetone for 5 min, and standard immunohistochemical protocol was used for monocyte/macrophage antibody (MOMA-2; Serotec). Negative controls included nonimmune isotype antibody or omission of the primary antibody.

For oil red O staining, frozen sections were fixed in 4% paraformaldehyde at room temperature for 30 min. After being washed in water for 2 min, slides were stained with 0.24% oil red O in 60% isopropanol for 20 min. After another wash in 60% isopropanol for 2 min, slides were counterstained with hematoxylin and fast green.

Collagen content in the plaque was identified using a standard Trichrome stain protocol. Collagen was identified as blue stain in tissue under a light microscope.

Serum cholesterol. Serum cholesterol levels were measured using a commercial kit (Sigma, St. Louis, MO).

RT-PCR. Total RNA was extracted from spleens using TRIzol (Invitrogen, Carlsbad, CA). Aliquots (1 µg) were then subjected to reverse transcription using oligo(dT) primers and the Superscript II system (Invitrogen). Equal aliquots were then used for PCR with previously described primers for murine beta-actin, IFN-{gamma}, IL-4 (21), IL-10 (34), and TGF-beta (6) Cycling conditions were optimized for each primer, and PCR products were run on 1.2% agarose gel stained with ethidium bromide. Gels were digitally photographed, and densitometric analysis was performed. Values are expressed as ratios to beta-actin.

Oxidized LDL antibodies. Antibodies to native LDL (nLDL) and malondialdehyde-oxidized LDL (MDA-LDL) were assayed using commercially available ELISA plates (catalog no. 1158; IMMCO Diagnostics, Buffalo, NY), and the manufacturer's recommended protocol was followed. The system is protected from oxidation because the plates are sealed in an oxygen-free atmosphere. Sera were diluted 1:10, and dilutions of more than 1:10 yielded values too low to interpret. Copper-oxidized LDL (Cu-oxLDL) Ig titers were assayed using LDL oxidized overnight with CuSO4 (5 µM). Plates were coated with 10 µg/ml Cu-oxLDL as capture antigen. Sera were diluted 1:50, incubated on coated plates for 2 h at 4°C, washed, and detected with horseradish peroxidase (HRP)-labeled anti-mouse IgG (Pierce) or anti-mouse IgM with the ABTS system (SBA). Specific isotypes were determined using Cu-oxLDL-coated plates and HRP-labeled anti-mouse IgG1 and IgG2a. Values are expressed as optical density at 405 nm (OD405).

Immune complex. Presence of immune complex formation in serum was detected using a modified ELISA. Goat anti-ApoB antibody (Santa Cruz Biotechnology) was coated on an ELISA plate as capture antibody overnight at 4°C. Sera were diluted 1:50 and incubated in the ELISA plate for 2 h at room temperature. Wells were washed, and detection was performed using anti-mouse Ig conjugated with HRP, with ABTS as substrate. Reproducibility of the assay was assessed using three to four replicates and dilutions and determining the coefficient of variation, which ranged from 3 to 5.4%.

PC antibodies. Antibodies to PC were assessed using ELISA on serially diluted serum samples. Briefly, ELISA plates were coated overnight with 10 µg/ml PC-keyhole limpet hemocyanin (KLH). Diluted sera were then incubated in the washed and preblocked ELISA wells for 1 h at room temperature, washed, and detected using HRP-labeled anti-mouse IgM and the ABTS system. Specificity and reproducibility were assessed using a mouse monoclonal antibody to PC (T15 IgA; Sigma) and blocking with KLH or PC-KLH. Results were expressed as OD405. Cross-reactivity to oxLDL was determined using a competition assay. Wild-type (WT) C57Bl6/J male mice purchased from Jackson ImmunoResearch Laboratory were fed normal chow, and serum was collected at 20, 40, and >52 wk for comparison to the antibody titers of hypercholesterolemic apoE(–/–) mice. Tissue was harvested from 24-, 40-, and >52-wk-old mice.

Total IgG and IgM. Total IgG and IgM titers were determined using a commercially available assay (SBA) with goat anti-mouse immunoglobulin to capture (5 µg/ml) and goat anti-mouse IgM-HRP (SBA) or goat anti-mouse IgG-HRP (Pierce) for detection. Serum dilutions were 1:100 as recommended.

Statistics. Values are expressed as means (SD). Group comparisons were performed using ANOVA followed by Tukey-Kramer post hoc tests, unless otherwise indicated. Statistical significance was set at the 0.05 level.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Atherosclerotic plaque extent and serum cholesterol. Increasing age was associated with increasing extent of atherosclerosis in the descending aorta. Atherosclerotic lesions were detected at 15–17 wk (n = 5), increased markedly at 36 wk (n = 6), and increased more so at >52 wk of age (n = 8; Fig. 1A). A similar age-related increase was also observed in the aortic sinus plaque area (Fig. 1B). Serum cholesterol levels were comparable and did not differ significantly across the various age groups (782 ± 161, 776 ± 380, and 611 ± 99 mg/dl, respectively).


Figure 1
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1. Percent atherosclerotic plaque area in the descending aorta, measured after en face preparation for lipid stain, increased as the mice aged (A). Atherosclerotic plaque area in the aortic sinus cross sections also increased as the mice aged (B). *P < 0.001 vs. 15–17 wk. {dagger}P < 0.001 vs. 36 wk. 15–17 wk, n = 5; 36 wk, n = 8; >52 wk, n = 6.

 
Phenotypic composition of aortic sinus plaque. The composition of aortic sinus plaques showed significant changes with a progressive decline in lipid content and macrophage (MOMA-2) immunoreactivity in the plaques with increasing age (Fig. 2, A and B). In contrast, collagen content increased with increasing age (Fig. 2C).


Figure 2
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2. Changes in the indexes of the atherosclerotic plaque over time. Percent intraplaque monocyte/macrophage (MOMA) immunoreactivity in cross sections of the sinus plaques gradually decreased over time (A), significantly in the >52 wk group. Intraplaque lipid content, determined by oil red O stain of the sinus plaque, also decreased in the older mice (B). There was a concomitant increase in plaque collagen content as stained by Trichrome in the aging mice (C). *P < 0.05; {dagger}P < 0.01 vs. 15–17 wk. {ddagger}P < 0.01; §P < 0.05 vs. 36 wk. 15–17 wk, n = 5; 36 wk, n = 8; >52 wk, n = 6.

 
Antibodies to MDA-LDL. To determine the changes of the adaptive immune response to oxLDL with age, we assessed antibody titers to oxLDL epitopes. We observed a different temporal expression pattern of antibodies against MDA-LDL between C57BL/6 and hypercholesterolemic apoE(–/–) mice. Antibodies to MDA-LDL of the IgM isotype did not significantly change between the age groups in apoE(–/–) mice (n > 5), whereas MDA-LDL IgM in WT mice increased from 20 to 40 wk and then decreased significantly from 40 to >52 wk (n = 4 each; Fig. 3A). MDA-LDL IgG antibodies in apoE(–/–) mice significantly increased from 15 to 17 (n = 5) to 36 wk (n = 6) and then decreased significantly from 36 to >52 wk (n = 6). WT MDA-LDL IgG antibodies had a similar temporal profile (Fig. 3B). Antibodies to nLDL showed a pattern similar to that of MDA-LDL IgG (Fig. 3C). The results suggest that although MDA-LDL IgM antibodies are affected by hypercholesterolemia, MDA-LDL IgG and nLDL IgG are not, and the observed changes are likely due to the aging immune system.


Figure 3
View larger version (25K):
[in this window]
[in a new window]
  		Fig. 3. Serum anti-malondialdehyde-oxidized LDL (MDA-LDL) IgM titers in apoE(–/–) mice did not change over time (A). MDA-LDL IgM titers in wild-type (WT) mice increased in 40-wk-old mice and decreased in >52-wk-old mice. MDA-LDL IgG titers, on the other hand, increased in both apoE(–/–) and WT mice (at 36 and 40 wk, respectively) and decreased at >52 wk (B). The native LDL (nLDL) IgG titers in both apoE(–/–) and WT mice followed a trend similar to that of the MDA-LDL IgG titers (C). *P < 0.05 vs. 40 wk. {dagger}P < 0.05 vs. 15–17 wk. {ddagger}P < 0.05 vs. 36 wk. §P < 0.05 vs. 20 wk. OD405, optical density at 405 nm.

 
IgM antibodies to Cu-oxLDL epitopes. The innate antibody response to oxLDL epitopes was assessed using IgM immune responses to Cu-oxLDL and PC. Cu-oxLDL IgM and PC IgM antibody titers in apoE(–/–) mice gradually increased with age, doubling at >52 wk (n = 6) compared with 15–17 wk (n = 5 for 15–17 and 36 wk; P < 0.05; Fig. 4, A and B). Cu-oxLDL IgM and PC IgM increased dramatically at 40 wk in the WT mice, more than double the levels at 20 wk (P < 0.05), and leveled-off (n = 4 each age group; Fig. 4, A and B). Anti-PC IgM was determined to cross-react with oxLDL by a competition assay using pooled sera from the mice (see Fig. 6A). Sera from each of the three different age groups were used to assess changes in serum apoB-IgM immune complexes. There was a progressive increase in serum apoB-IgM immune complex in apoE(–/–) mice, which was doubled at >52 wk (n = 6 each for 15–17 and >52 wk, n = 4 for 36 wk; Fig. 4C). No differences were observed in the apoB-IgM immune complex in WT mice (n = 6 for 20 wk, n = 4 for 40 and >52 wk; Fig. 4C).


Figure 4
View larger version (23K):
[in this window]
[in a new window]
  		Fig. 4. Copper-oxidized LDL (Cu-oxLDL) IgM (A) and phosphorylcholine (PC)-IgM (B) in apoE(–/–) mice gradually increased over time, reaching statistical significance at >52 wk. In the WT mice, the increase was more abrupt at the 40-wk time point and leveled off. Circulating apoB-IgM immune complexes in apoE(–/–) mice gradually increased over time, doubling by >52 wk (C). No differences were observed in WT mice. *P < 0.05 vs. 15–17 wk. {dagger}P < 0.05 vs. 20 wk.

 

Figure 6
View larger version (21K):
[in this window]
[in a new window]
  		Fig. 6. PC-IgM was successfully competed with Cu-oxLDL (A). Total serum IgM in apoE(–/–) mice slightly increased at >52 wk of age. Total serum IgM in WT mice was not different (B). Total serum IgG in apoE(–/–) mice was also slightly increased at >52 wk but was unchanged in the WT mice (C). *P < 0.01 and {dagger}P < 0.05 vs. 15–17 wk. B/B0, ratio indicating cross-reactivity of antibody compared with no competitor (oxLDL) added.

 
IgG antibodies to Cu-oxLDL epitopes. Cu-oxLDL IgG titers also increased progressively with age in the apoE(–/–) mice (n = 5 each for 15–17 and 36 wk, n = 6 for >52 wk; Fig. 5A). This increase was not isotype specific, because both IgG1 and IgG2a increased to a similar degree (n = 4 for 15–17 wk, n = 5 for 36 wk, n = 6 for >52 wk; Fig. 5B). WT Cu-oxLDL IgG titers were again increased more than twofold at 40 wk (n = 4) compared with 20 wk (n = 3; P < 0.05) and remained so at >52 wk (n = 4; Fig. 5A). There was no change in the immune complexes of apoE(–/–) mice from 15–17 (n = 6) to 36 wk (n = 4). However, there was a sixfold increase from 36 to >52 wk (n = 6; P < 0.05; Fig. 5C). No changes were observed in WT serum immune complex at any time point (n = 6 for 20 wk, n = 4 each for 40 and >52 wk; Fig. 5C).


Figure 5
View larger version (22K):
[in this window]
[in a new window]
  		Fig. 5. Cu-oxLDL IgG titers in the apoE(–/–) mice gradually increased from the 15- to 17-wk-old group to the 36-wk-old group and significantly increased in the >52-wk-old group (A). The change in Cu-oxLDL titers was not isotype specific, because both IgG1 and IgG2a increased in a similar manner (B). Cu-oxLDL IgG in WT mice significantly increased at 40 wk and leveled off at >52 wk (A). Circulating apoB-IgG immune complexes (IC) in apoE(–/–) mice were not changed between 15 and 17 and 36 wk but were significantly increased at >52 wk (C). No differences in circulating apoB-IgG IC were observed in the WT mice (C). *P < 0.01; **P < 0.05 vs. 15–17 wk. {dagger}P < 0.05 vs. 36 wk. {ddagger}P < 0.01; §P < 0.05 vs. 20 wk.

 
Total immunoglobulin. There was a very slight but statistically significant increase in total IgG and IgM levels in apoE(–/–) mice at >52 wk (n = 4 for 15–17 wk, n = 5 for 36 wk, n = 6 for >52 wk; Fig. 6A). This change was not observed in the WT mice (n = 4 each; Fig. 6, B and C).

Splenic cytokine profile. Using RT-PCR, we further determined the cytokine expression pattern from spleens in apoE(–/–) mice in relation to aging (Fig. 7 and Table 1). The expression of IFN-{gamma}, IL-4, and IL-10 were low in 15- to 17-wk-old mice, gradually increased in mice at 36 wk of age, and significantly increased in mice >52 wk of age. TGF-beta mRNA expression had a slight increase at the oldest time point tested (n = 3 each). Splenic cytokine expression in WT mice also increased at 40 wk and was maintained to >52 wk (Table 2).


Figure 7
View larger version (36K):
[in this window]
[in a new window]
  		Fig. 7. RT-PCR of splenic RNA from apoE(–/–) mice. Low-level IL-4 expression was detected in 15- to 17-wk-old mice, gradually increased in 36-wk-old mice, and significantly increased in >52-wk-old mice (P < 0.05 vs. 15–17 wk; n = 4 each). Similarly, IL-10 had a low level of expression in 15- to 17-wk-old mice, which variably increased in 36-wk-old mice and significantly increased in >52-wk-old mice (P < 0.05 vs. 15–17 wk; n = 3 each). IFN-{gamma} expression was detected at low levels in 15- to 17-wk-old mice, gradually increased in 36-wk-old mice, and significantly increased in >52-wk-old mice (P < 0.05 vs. 15–17 wk old; n = 4 each). TGF-beta mRNA expression slightly increased at the oldest time point tested (n = 3 each). beta-actin was used as reference.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Temporal course of splenic cytokine expression assessed by RT-PCR

 

View this table:
[in this window]
[in a new window]
  		Table 2. Temporal course of splenic cytokine expression in WT mice assessed by RT-PCR

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Aging is a major risk factor for the development of diseases such as cancer or atherosclerosis. Although a dysfunctional immune response has been shown to be an important underlying mechanism for atherosclerosis (3, 15, 40), how different indexes of immune responses to atherosclerosis change with aging has not been systematically described. A previous report (24) tracked the changes in MDA-LDL antibody titers and the development of atherosclerosis in LDL receptor-deficient [LDLR(–/–)] mice but did not proceed beyond 36–40 wk of age. We therefore initiated a longitudinal study of the indexes of atherosclerosis during aging as they relate to immune functions in hypercholesterolemic apoE(–/–) mice. Our results indicate that specific changes in disease progression occurred with concomitant shifts in immune responses to oxLDL epitopes, which are among the many proposed immunogens involved in atherosclerosis.

This study shows that advanced age is associated with changes in aortic atherosclerotic plaque composition characterized by decreased intraplaque lipid and macrophage, and increased collagen content, suggesting a more stable plaque phenotype. These changes occurred without any significant changes in circulating cholesterol levels. Our findings are consistent with a previous report (25) that the atherosclerotic lesions in aortic sinus became less cellular and were covered with fibrous cap as hypercholesterolemic apoE(–/–) mice aged. Convincing experimental models of spontaneous plaque rupture in mouse have been difficult, if not impossible, to obtain (9, 26). This could be due to the observed increase of collagen content and reduction of lipid and macrophage content in the plaques as mice aged, and the clinical observation that the vulnerability of atherosclerotic plaques to rupture is not a linear function of the plaque burden (8, 29, 30).

Because of the known link between atherosclerosis and antibody response to oxLDL (24), we sought to determine whether the change in plaque phenotype and increase in size were associated with changes in antibody responses to oxLDL epitopes. The temporal courses of antibody response to MDA-LDL or Cu-oxLDL are distinctly different. IgG antibody titers to MDA-LDL increased in the 36-wk-old mice but clearly decreased in the older mice (>52 wk), whereas Cu-oxLDL IgG and IgM antibody titers increased gradually between 15 and 17 wk and 36 wk, and significantly from 36 to >52 wk. The increase in MDA-LDL titers at 36 wk of age is in agreement with a previous report (24) characterizing MDA-LDL antibody response in LDLR(–/–) mice. The changes in MDA-LDL IgG titers appear to be related to aging rather than to atherosclerotic disease progression, since nondiseased WT mice had a very similar profile to that of apoE(–/–) mice. Interestingly, although MDA-LDL IgM changes occurred in WT mice, this was not observed in apoE(–/–) mice.

The innate immune antibody response in atherosclerosis has gained interest with the characterization of an IgM antibody against oxLDL shown to be identical to T15, which is a PC-reactive antibody, identifying PC as a recognizable epitope on oxidatively modified LDL (31). PC is a known autoantigen involved in educating the host innate immune response to produce antibodies involved in the first response to infectious challenges (16, 32). We therefore used PC as an antigen to assess innate antibody response to oxLDL in our study. PC-IgM titers had age-related kinetics similar to Cu-oxLDL IgM. Cross-reactivity between PC IgM and Cu-oxLDL was confirmed by competition assay. The importance of the molecular mimicry observed between Cu-oxLDL and PC is underscored by the observed cross-reactivity between antibodies to PC-bearing dental plaque bacteria and oxLDL epitopes (28).

The IgM response to Cu-oxLDL and PC-bearing epitopes in the WT mice has different kinetics compared with apoE(–/–) mice during the aging process. Although a pattern of progressive increase in IgM antibody titers was observed in the apoE(–/–) mice, the increase in the WT mice was rather abrupt between 20 and 40 wk of age and then subsequently leveled off, not increasing further (Fig. 4, A and B). One possible explanation to account for this difference is that the apoE(–/–) mice were under constant immunologic pressure from hypercholesterolemia, and hence the immune response continued to mount with aging. It is noteworthy that detectable circulating apoB-IgM immune complex paralleled the progressive increase in IgM titers in apoE(–/–) mice. There were no changes in detectable apoB-IgM immune complex titers in WT mice.

Cu-oxLDL IgG titers increased in a manner similar to the IgM titers. As in the IgM titers, apoE(–/–) mice progressed to high Cu-oxLDL IgG titers over time, whereas WT mice again abruptly increased titers and leveled off. The spontaneous increase in Cu-oxLDL IgG titers in apoE(–/–) mice was not associated with a shift in isotype response (Fig. 5B). The dramatic increase in detectable apoB-IgG immune complexes in the >52-wk-old group occurred concomitantly with increased Cu-oxLDL IgG titers and decreased intraplaque lipid and macrophage, suggesting increased clearance of Cu-oxLDL epitopes, which contain apoB. This may represent a pathway for atheroprotective effects of increased antibody response to Cu-oxLDL. The increase in antibody levels in the apoE(–/–) mice occurred also, because the total IgG and IgM levels slightly increased. Although statistically significant, it is unclear whether the very slight changes are physiologically relevant.

Caligiuri et al. (5) reported that sex and age affect splenic T-cell proliferative response in vitro. The cultured splenocytes from old male apoE(–/–) mice (48 wk old) developed a stronger proliferative response against Cu-oxLDL compared with those from young male mice (16 wk old), yet there was minimal difference in the response against MDA-LDL between splenocytes from young and old mice. This observation is in line with our data that antibody response against Cu-oxLDL increased with age and had a different temporal course compared with the antibody response against MDA-LDL.

It has been reported that splenic T or B lymphocyte populations do not differ significantly with age in apoE(–/–) mice. Although the number of CD4 subset of T lymphocytes slightly increased with age, the CD8 subset of T lymphocytes decreased with age (5). We have further extended these observations and report that there was a general increase in splenic cytokine expression with age. This finding is in line with previous studies of aging WT mice (17, 18, 38). It is unclear whether the increase in cytokine expression is the result of activation by a specific oxLDL epitope.

The physiological meaning of the increased antibody titers against LDL with age is unclear at present. It is also unknown whether it is a response or a contributor to the progressively increased atherosclerotic burden. The increase in nondiseased mice would argue for either a protective effect or a bystander role. Experimental evidence has shown that augmentation of antibody response to LDL by immunization reduces atherosclerotic plaque size (1, 7, 11, 14), and splenectomy reduced antibody response to LDL with concomitant increase in plaque burden (4); hence, it is reasonable to speculate that such an increase of antibody response to LDL with age could be atheroprotective but occurred too late (7). Further experiments are needed to test this hypothesis.

Our results have certain clinical implications. Numerous studies have been published to establish a relationship between circulating oxLDL antibodies and atherosclerotic disease; however, the results have been conflicting. Some studies showed a higher oxLDL antibody titer in patients with clinical disease (2, 10, 22, 27, 39), whereas others showed inverse relationship between oxLDL antibody titers and measured atherosclerotic end points (12, 19) or no relationship at all (20, 35, 36). It is difficult to account for the reported discrepancies, but they may be due to differences in experimental design (prospective study vs. case control study), oxLDL antibody and its isotype measured (MDA-LDL vs. Cu-oxLDL, IgG vs. IgM), or atherosclerotic end points measured (clinical myocardial infarction vs. angiographic coronary artery disease vs. carotid intimal-medial thickening vs. healthy subjects). Age of the studied subjects is another important factor, because these studies often enrolled patients with a wide range of age. Our observation that the measured atherosclerotic indexes related to LDL varied with age supports such a view and is consistent with a recent longitudinal human study (33).

In conclusion, our study delineates the natural temporal course of changes in indexes of atherosclerosis and its related changes in the immune responses, which are important in understanding the dynamics of immune response against LDL or its related epitopes and the evolution of atherosclerosis with age.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by a grant from the Eisner Foundation, the Heart Fund at Cedars-Sinai Medical Center, United Hostesses Charities, and The Milken Foundation.


   ACKNOWLEDGMENTS
 
We thank Prediman K. Shah, MD, and Bojan Cercek, MD, PhD, for critical reviews of this manuscript. We also thank Ang Ji and Carmel Ferreira for technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: K.-Y. Chyu, Division of Cardiology, Cedars-Sinai Medical Center, Rm. 5621, 8700 Beverly Blvd., Los Angeles, CA 90048

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* P. C. Dimayuga and K.-Y. Chyu contributed equally to this work. Back


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, Shah PK, and Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16: 1074–1079, 1996.[Abstract/Free Full Text]
  2. Bergmark C, Wu R, de FU, Lefvert AK, and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15: 441–445, 1995.[Abstract/Free Full Text]
  3. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, and Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med 8: 1218–1226, 2002.[CrossRef][ISI][Medline]
  4. Caligiuri G, Nicoletti A, Poirier B, and Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109: 745–753, 2002.[CrossRef][ISI][Medline]
  5. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, and Hansson GK. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145: 301–308, 1999.[CrossRef][ISI][Medline]
  6. Chow JF, Lee KF, Chan ST, and Yeung WS. Quantification of transforming growth factor beta1 (TGFbeta1) mRNA expression in mouse preimplantation embryos and determination of TGFbeta receptor (type I and type II) expression in mouse embryos and reproductive tract. Mol Hum Reprod 7: 1047–1056, 2001.[Abstract/Free Full Text]
  7. Chyu KY, Reyes OS, Zhao X, Yano J, Dimayuga P, Nilsson J, Cercek B, and Shah PK. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (–/–) mice. Atherosclerosis 176: 27–35, 2004.[CrossRef][ISI][Medline]
  8. Chyu KY and Shah PK. The role of inflammation in plaque disruption and thrombosis. Rev Cardiovasc Med 2: 82–91, 2001.[Medline]
  9. Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, von EA, Exley A, Goddard M, Hofker M, Hurt-Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W, Pentikainen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B, and de Winther M for the MAFAPS Consortium. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol 23: 535–542, 2003.[Abstract/Free Full Text]
  10. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, and Yla-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20: 204–209, 2000.[Abstract/Free Full Text]
  11. Freigang S, Horkko S, Miller E, Witztum JL, and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18: 1972–1982, 1998.[Abstract/Free Full Text]
  12. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, and Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20: 703–707, 2000.[Abstract/Free Full Text]
  13. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, and Shoenfeld Y. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98: 1108–1115, 1998.[Abstract/Free Full Text]
  14. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, and Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147–152, 1998.[CrossRef][ISI][Medline]
  15. Hansson GK, Libby P, Schonbeck U, and Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91: 281–291, 2002.[Abstract/Free Full Text]
  16. Harnett W and Harnett MM. Phosphorylcholine: friend or foe of the immune system? Immunol Today 20: 125–129, 1999.[CrossRef][ISI][Medline]
  17. Hobbs MV, Weigle WO, and Ernst DN. Interleukin-10 production by splenic CD4+ cells and cell subsets from young and old mice. Cell Immunol 154: 264–272, 1994.[CrossRef][ISI][Medline]
  18. Hobbs MV, Weigle WO, Noonan DJ, Torbett BE, McEvilly RJ, Koch RJ, Cardenas GJ, and Ernst DN. Patterns of cytokine gene expression by CD4+ T cells from young and old mice. J Immunol 150: 3602–3614, 1993.[Abstract]
  19. Hulthe J, Wiklund O, Hurt-Camejo E, and Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A2. Arterioscler Thromb Vasc Biol 21: 269–274, 2001.[Abstract/Free Full Text]
  20. Iribarren C, Folsom AR, Jacobs DR, Gross MD, Belcher JD, and Eckfeldt JH. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study. The ARIC Study Investigators. Atherosclerosis Risk in Communities. Arterioscler Thromb Vasc Biol 17: 1171–1177, 1997.[Abstract/Free Full Text]
  21. Lee TS, Yen HC, Pan CC, and Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19: 734–742, 1999.[Abstract/Free Full Text]
  22. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, Yla-Herttuala S, Luoma JS, Koivula T, and Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19: 23–27, 1999.[Abstract/Free Full Text]
  23. Palinski W, Miller E, and Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92: 821–825, 1995.[Abstract/Free Full Text]
  24. Palinski W, Tangirala RK, Miller E, Young SG, and Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15: 1569–1576, 1995.[Abstract/Free Full Text]
  25. Reddick RL, Zhang SH, and Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14: 141–147, 1994.[Abstract/Free Full Text]
  26. Rekhter MD. How to evaluate plaque vulnerability in animal models of atherosclerosis? Cardiovasc Res 54: 36–41, 2002.[Abstract/Free Full Text]
  27. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, and Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883–887, 1992.[CrossRef][ISI][Medline]
  28. Schenkein HA, Berry CR, Purkall D, Burmeister JA, Brooks CN, and Tew JG. Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins. Infect Immun 69: 6612–6617, 2001.[Abstract/Free Full Text]
  29. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41, Suppl S: 15S–22S, 2003.[Abstract/Free Full Text]
  30. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 21: 303–314, 2003.[CrossRef][Medline]
  31. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, and Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105: 1731–1740, 2000.[ISI][Medline]
  32. Sigal NH, Gearhart PJ, and Klinman NR. The frequency of phosphorylcholine-specific B cells in conventional and germfree BALB/C mice. J Immunol 114: 1354–1358, 1975.[Abstract/Free Full Text]
  33. Tinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Esteva I, Ruiz de Adana MS, Cardona F, and Soriguer F. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 46: 452–457, 2005.[Abstract/Free Full Text]
  34. Ulett GC, Ketheesan N, and Hirst RG. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect Immun 68: 2034–2042, 2000.[Abstract/Free Full Text]
  35. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, and Yla-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16: 1236–1242, 1996.[Abstract/Free Full Text]
  36. Vande Vijver LP, Steyger R, van PG, Boer JM, Kruijssen DA, Seidell JC, and Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122: 245–253, 1996.[CrossRef][ISI][Medline]
  37. Vanden Elzen p Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, and Brenner MB. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437: 906–910, 2005.[CrossRef][Medline]
  38. Wakikawa A, Utsuyama M, Wakabayashi A, Kitagawa M, and Hirokawa K. Age-related alteration of cytokine production profile by T cell subsets in mice: a flow cytometric study. Exp Gerontol 34: 231–242, 1999.[CrossRef][ISI][Medline]
  39. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, and Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 17: 3159–3163, 1997.[Abstract/Free Full Text]
  40. Yung RL. Changes in immune function with age. Rheum Dis Clin North Am 26: 455–473, 2000.[CrossRef][ISI][Medline]
  41. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, and Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 108–114, 2001.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/R1644    most recent
00511.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimayuga, P. C.
Right arrow Articles by Chyu, K.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimayuga, P. C.
Right arrow Articles by Chyu, K.-Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.